Article
Metabologenomic characterization uncovers a clinically aggressive IDH mutant glioma subtype.
Acta neuropathologica - 7 Apr 2024
Nassiri Farshad, Ajisebutu Andrew, Patil Vikas, Mamatjan Yasin, Liu Jeff, Wang Justin Z, Voisin Mathew R, Nejad Romina, Mansouri Sheila, Karimi Shirin, Chakravarthy Ankur, Chen Eric, De Carvalho Daniel D, Aldape Kenneth, Zadeh Gelareh
Abstract excerpt
Mutations in the pivotal metabolic isocitrate dehydrogenase (IDH) enzymes are recognized to drive the molecular footprint of diffuse gliomas, and patients with IDH mutant gliomas have overall favorable outcomes compared to patients with IDH wild-type tumors. However, survival still varies widely among patients with IDH mutated tumors. Here, we aimed to characterize molecular signatures that explain the range of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.